SCHEMBL17640277

SCHEMBL17640277

COc1c(F)cccc1-c1n[nH]c2ncc(Nc3ccc(N4CCOCC4)c(Cl)c3)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.43
▸ MAPT P10636 6/20 0.43
▸ NPC1 O15118 4/20 0.43
▸ RAB9A P51151 4/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ NFKB1 P19838 2/20 0.43
▸ NFKB2 Q00653 2/20 0.43
▸ RELA Q04206 2/20 0.43
▸ BCL6 P41182 1/20 0.42
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ ALDH1A1 P00352 5/20 0.40
▸ HPGD P15428 3/20 0.40
▸ HTT P42858 4/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ TNIK Q9UKE5 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17639943 0.90 EGFR (0.43) EGFRMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL15805392 0.86 CLK1 (0.46) EGFRMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL17640327 0.84 JAK2 (0.49) JAK2JAK3PTK2KCNH2
SCHEMBL15805384 0.78 CLK1 (0.46) EGFRMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL17636833 0.75 PDE7A (0.39) MAPTCHEK1LRRK2TYK2
SCHEMBL17640273 0.74 AXL (0.48) EGFRCCNT1CDK9JAK2CSF1R
SCHEMBL17636863 0.74 AR (0.51) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL12342848 0.71 JAK2 (0.53) RAB9AMEN1KMT2AHPGDJAK2
SCHEMBL15805447 0.70 JAK2 (0.49) EGFRJAK2RPS6KA3JAK3PTK2
SCHEMBL17636830 0.67 BTK (0.39) MAPTNPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951062-B2 Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors ARRIEN PHARMACEUTICALS LLC (US) 2018-04-24 — — US disclosed
US-20160090382-A1 Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors ARRIEN PHARMACEUTICALS LLC 2016-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160090382-A1 Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors SIK2, SIK1, SIK3 EGFR 2026/4885MAPT 3252/4885NPC1 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback